257 related articles for article (PubMed ID: 25504564)
1. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.
Posada MM; Bacon JA; Schneck KB; Tirona RG; Kim RB; Higgins JW; Pak YA; Hall SD; Hillgren KM
Drug Metab Dispos; 2015 Mar; 43(3):325-34. PubMed ID: 25504564
[TBL] [Abstract][Full Text] [Related]
2. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
Sweeney CJ; Takimoto CH; Latz JE; Baker SD; Murry DJ; Krull JH; Fife K; Battiato L; Cleverly A; Chaudhary AK; Chaudhuri T; Sandler A; Mita AC; Rowinsky EK
Clin Cancer Res; 2006 Jan; 12(2):536-42. PubMed ID: 16428497
[TBL] [Abstract][Full Text] [Related]
3. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3.
Kurata T; Iwamoto T; Kawahara Y; Okuda M
Drug Metab Pharmacokinet; 2014; 29(2):148-53. PubMed ID: 24042472
[TBL] [Abstract][Full Text] [Related]
5. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.
Posada MM; Cannady EA; Payne CD; Zhang X; Bacon JA; Pak YA; Higgins JW; Shahri N; Hall SD; Hillgren KM
Clin Transl Sci; 2017 Nov; 10(6):509-519. PubMed ID: 28749581
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.
Lau CL; Chan ST; Selvaratanam M; Khoo HW; Lim AY; Modamio P; Mariño EL; Segarra I
Fundam Clin Pharmacol; 2015 Aug; 29(4):404-16. PubMed ID: 26011058
[TBL] [Abstract][Full Text] [Related]
11. Quantitative prediction of renal transporter-mediated clinical drug-drug interactions.
Feng B; Hurst S; Lu Y; Varma MV; Rotter CJ; El-Kattan A; Lockwood P; Corrigan B
Mol Pharm; 2013 Nov; 10(11):4207-15. PubMed ID: 24066726
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Varma MV; Lai Y; Feng B; Litchfield J; Goosen TC; Bergman A
Pharm Res; 2012 Oct; 29(10):2860-73. PubMed ID: 22638872
[TBL] [Abstract][Full Text] [Related]
13. Distribution of the novel antifolate pemetrexed to the brain.
Dai H; Chen Y; Elmquist WF
J Pharmacol Exp Ther; 2005 Oct; 315(1):222-9. PubMed ID: 15987831
[TBL] [Abstract][Full Text] [Related]
14. Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling.
Ball K; Jamier T; Parmentier Y; Denizot C; Mallier A; Chenel M
Eur J Pharm Sci; 2017 Aug; 106():122-132. PubMed ID: 28552429
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil.
Pak YA; Posada MM; Bacon J; Long A; Annes W; Witcher J; Mitchell M; Tirona RG; Hall SD; Hillgren KM
Pharm Res; 2023 Nov; 40(11):2499-2511. PubMed ID: 36635486
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
Britz H; Hanke N; Taub ME; Wang T; Prasad B; Fernandez É; Stopfer P; Nock V; Lehr T
Pharm Res; 2020 Nov; 37(12):250. PubMed ID: 33237382
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the effect of voriconazole on the pharmacokinetics of non-steroidal anti-inflammatory drugs.
Li N; Zhu L; Qi F; Li M; Xu G; Ge T
J Chemother; 2018 Jul; 30(4):240-246. PubMed ID: 30375950
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.
Ouellet D; Periclou AP; Johnson RD; Woodworth JR; Lalonde RL
Cancer Chemother Pharmacol; 2000; 46(3):227-34. PubMed ID: 11021740
[TBL] [Abstract][Full Text] [Related]
19. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1.
Masuda S; Saito H; Inui KI
J Pharmacol Exp Ther; 1997 Dec; 283(3):1039-42. PubMed ID: 9399974
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
Feng B; Varma MV
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
